Claims for Patent: 8,815,884

Summary for Patent: 8,815,884

Title:	Prolyl hydroxylase inhibitors
Abstract:	The invention described herein relates to certain pyrimidinetrione N-substituted glycine derivatives of formula (I) which are antagonists of HIF prolyl hydroxylases and are useful for treating diseases benefiting from the inhibition of this enzyme, anemia being one example.
Inventor(s):	Duke M. FITCH, Antony N. Shaw, Kenneth Wiggall
Assignee:	GlaxoSmithKline LLC
Application Number:	US14/026,164
Patent Claims:	1. A pharmaceutical composition for oral administration which comprises 1-700 mg of the compound: or a salt thereof and one or more pharmaceutically acceptable carriers, diluents or excipients. 2. A pharmaceutical composition for oral administration which comprises 1-700 mg of the compound: and one or more pharmaceutically acceptable carriers, diluents or excipients. 3. The pharmaceutical composition of claim 2, wherein said pharmaceutical composition comprises 5-100 mg of said compound. 4. A method of treating anemia associated with renal disease in a human comprising administering to such patient a pharmaceutical composition according to claim 1. 5. A method of treating anemia associated with renal disease in a human comprising administering to such patient a pharmaceutical composition according to claim 2. 6. A method of treating anemia associated with renal disease in a human comprising administering to such patient a pharmaceutical composition according to claim 3. 7. The method of claim 4, wherein said pharmaceutical composition is administered as a daily dose. 8. The method of claim 5, wherein said pharmaceutical composition is administered as a daily dose. 9. The method of claim 6, wherein said pharmaceutical composition is administered as a daily dose.